Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials

Statistics in Medicine

Volumn 32, Issue 10, 2013, Pages 1691-1706

  Quan, Hui ^a   Li, Mingyu ^b   Shih, Weichung Joe ^c   Ouyang, Soo Peter ^b   Chen, Joshua ^d   Zhang, Ji ^a   Zhao, Peng Liang ^a  

^a SANOFI   (France)

^b CELGENE CORPORATION   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Random effect model; Sample size; Type I error rate; Weighted estimator

Indexed keywords

ACCURACY; ALGORITHM; ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; EMPIRICAL SHRINKAGE ESTIMATOR; HUMAN; INTERNAL CONSISTENCY; MATHEMATICAL MODEL; MULTICENTER STUDY (TOPIC); NORMAL DISTRIBUTION; PROBABILITY; RANDOM ERROR; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; STUDY DESIGN; TREATMENT OUTCOME;

BAYES THEOREM; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DELAYED-ACTION PREPARATIONS; DRUG DISCOVERY; HEART FAILURE; HUMANS; METOPROLOL; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TIME FACTORS;

EID: 84876454031     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5543     Document Type: Article

References (28)

1. The US Federal Register. Ethnic factor in the acceptability of foreign data. International Conference on Harmonisation; Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data; Federal Register 1998; 63:31790-31796. (Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073117.pdf) [Accessed date: July 17, 2012].
2. Senn SJ.Added values: controversies concerning randomization and additivity in clinical trials. Statistics in Medicine 2004; 23(24):3729-3753.
3. Shih WJ.Clinical trials for drug registrations in Asian-Pacific countries: proposal for a new paradigm from a statistical perspective. Controlled Clinical Trials 2001; 22:357-366.
4. Shih WJ.From bridging studies to global trial development. FDA-Industry Statistics Workshop, Washington DC, September 29, 2006. (Available at: http://www.amstat.org/meetings/fdaworkshop/index.cfm?fuseaction=2006presentations) [Accessed date: July 17, 2012].
5. Ministry of Health LaWoJ. Basic Concepts for Joint International Clinical Trials. September 28, 2007.
6. European Medicines Agency. Reflection paper on the extrapolation of results from clinical studies conducted outside Europe to the EU-population (draft). EMEA Doc. Ref. CHMP/EWP/692702/2008. February 2009. (Available at: http://www.emea.europa.eu/pdfs/human/ewp/69270208en.pdf) [Accessed date: July 17, 2012].
7. Kawai N, Chuang-Stein C, Komiyama O, Li Y.An approach to rationalize partitioning sample size into individual regions in a multiregional trial. Drug Information Journal 2007; 42:139-147.
8. Quan H, Zhao PL, Zhang J, Roessner M, Aizawa K.Sample size considerations for Japanese patients in a multi-regional trial based on MHLW Guidance. Pharmaceutical Statistics 2010; 9:100-112.
9. Quan H, Li M, Chen J, Gallo P, Binkowitz B, Ibia E, Tanaka Y, Ouyang SP, Luo X, Li G, Menjoge S, Talerico S, Ikeda K.Assessment of consistency of treatment effects in multiregional clinical trials. Drug information Journal 2010; 44:617-632.
10. Chen J, Quan H, Binkowitz B, Ouyang SP, Tanaka Y, Li G, Menjoge S, Ibia E.Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review. Pharmaceutical Statistics 2010; 9:242-253.
11. Uesaka H.Sample size allocation to regions in a multiregional trial. Journal of Biopharmaceutical Statistics 2009; 19:580-594.
12. O'Hagan A, Stevens JW, Campbell MJ.Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4:187-201.
13. Higgins JPT, Thompson SG.Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; 21:1539-1558.
14. Gallo P.Center-weighting issues in multicenter clinical trials. Journal of Biopharmaceutical Statistics 2001; 10:145-163.
15. Jones B, Teather D, Wang J, Lewis JA.A comparison of various estimators of a treatment difference for a multi-centre clinical trial. Statistics in Medicine 1998; 17:1767-77.
16. Fedorov V, Jones B.The design of multicentre trials. Statistical Methods in Medical Research 2005; 14:205-48.
17. Senn SJ.The many modes of meta. Drug Information Journal 2000; 34:535-549.
18. Senn SJ.Some controversies in planning and analysing multi-centre trials. Statistics in Medicine 1998; 17:1753-1765.
19. Hung HMJ, Wang SJ, O'Neill RT.Consideration of regional difference in design and analysis of multi-regional trials. Pharmaceutical Statistics 2010; 9:173-178.
20. Higgins JP, Thompson SG, Spiegelhalter DJ.A re-evaluation of random effects meta-analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society) 2009; 172:137-159.
21. Li Z, Chuang-Stein C, Hoseyni C.The probability of observing negative subgroup results when the treatment effect is positive and homogenous across all subgroups. Drug information Journal 2007; 41:47-56.
22. Chen YH, Wu YC, Wang M.A Bayesian approach to evaluating regional treatment effect in a multiregional trial. Journal of Biopharmaceutical Statistics 2009; 19:900-915.
23. Willan AR, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW.Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Economics 2005; 14:327-338.
24. Pinto EM, Willan AR, O'Brien BJ.Cost-effectiveness analysis for multinational clinical trials. Statistics in Medicine 2005; 24:1965-1982.
25. Gail M, Simon R.Testing for qualitative interaction between treatment effects and patient subsets. Biometrics 1985; 41:361-372.
26. Morris CN.Parametric empirical Bayes inference: theory and applications. Journal of the American Statistical Association 1983; 78:47-55.
27. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). The Lancet 1999; 353:2001-2007.
28. Wedel H, DeMets D, Deedwania P, Fagerberg B, Goldstein S, Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J.Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF. American Heart Journal 2001; 142:502-511.